EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population
Abstract
Authors
K Sutton P Miller N Branscombe M Mittal C Browne S Arnetorp T Henry K Breslin G Bungey J Quint H Montgomery